Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02286843
Title Can HER2 Targeted 89Zr-trastuzumab PET/CT Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan-Kettering Cancer Center

Her2-receptor negative breast cancer



Age Groups: adult
Covered Countries USA

No variant requirements are available.